Sector News

Industry experts weigh in on slew of bills aimed at drug price transparency at hearing

May 22, 2019
Life sciences

Experts from across the healthcare system weighed in on several House bills aimed at increasing transparency in the pharmaceutical supply chain at a hearing Tuesday.

Seven pieces of legislation, all of which are bipartisan, were on the slate for discussion at the House Energy and Commerce Committee Subcommittee on Health hearing. Amid the political fervor over rising drug prices, shining a light on how prices are determined has been a key focus for policymakers.

However, some in the industry warn that there may be too much of a good thing and that making all data public could undermine the goal of bringing down costs. Kristin Bass, chief policy and external affairs officer for the Pharmaceutical Care Management Association (PCMA), said the group backs releasing data on rebates and negotiations in “aggregate.”

But the pharmacy benefit management (PBM) trade group fears that fully public data would prevent effective negotiation with drug companies, Bass said.

“We have issues around public reporting when it would allow for tacit collusion” among drugmakers, she said.

Mark Miller, executive vice president of healthcare at Arnold Ventures, said greater transparency could “compel the issue forward.” However, on its own, transparency isn’t going to revolutionarily change how drugs are priced, he said.

None of the bills in question for Tuesday’s hearing would have forced PBMs to publicly disclose individual rebates negotiated for specific drugs, though one would make them release the data in aggregate.

Bass said that PCMA would recommend policymakers release such data by class for those with at least three drugs. It also suggests a lag time of several years for the data to be published to allow PBMs to adjust to existing contracts.

The ongoing debate on whether to eliminate rebates negotiated by PBMs entirely from the system was also on the slate at the hearing. Legislators pushed back on the fact that some PBMs will put drugs with higher list prices on the formulary instead of lower-cost alternatives.

Bass said insurers select drugs with the lowest net price—the price after rebates and other discounts have been factored in—and often that’s the drug with the higher list price.

Eliminating rebates, she said, would not put pressure on drug companies to lower list prices on their own, a point that others in the insurance industry have also noted. Studies have also suggested that the Trump administration’s plan to do so in Part D would increase premiums and taxpayer spending.

That said, the industry should indeed be looking at the concerns raised by rebates’ critics, she said.

“We do think there is a conversation to be around the price concessions,” Bass said.

By Paige Minemyer

Source: Fierce Healthcare

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach